Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9BQ65
UPID:
USB1_HUMAN
Alternative names:
3'-5' RNA exonuclease USB1; Mutated in poikiloderma with neutropenia protein 1
Alternative UPACC:
Q9BQ65; B4DWE3; B4DZW5; Q96FZ9; Q9H8X8
Background:
U6 snRNA phosphodiesterase 1, also known as 3'-5' RNA exonuclease USB1, plays a crucial role in RNA processing. It trims the 3' end of oligo(U) and oligo(A) tracts of pre-U6 small nuclear RNA (snRNA), leading to mature U6 snRNA formation. This protein is essential for U6 snRNA 3' end processing, preventing its degradation and ensuring the stability of RNA molecules involved in critical cellular functions.
Therapeutic significance:
Given its pivotal role in RNA processing and stability, U6 snRNA phosphodiesterase 1 is linked to Poikiloderma with neutropenia, a genodermatosis characterized by skin abnormalities and increased susceptibility to infections. Understanding the role of U6 snRNA phosphodiesterase 1 could open doors to potential therapeutic strategies for treating this disorder and possibly other RNA-related diseases.